Buy. Incyte scores 91/100 on Growth Compounder metrics, driven by 18% revenue CAGR and expanding specialty pharma margins, while a 77/100 Value Compounder score at 18.1× forward P/E reflects reasonable valuation for the biotech cohort. Key risk: JAKAFI patent cliff in 2028 and concentrated distribution through limited specialty pharmacies create meaningful revenue vulnerability—success hinges on pipeline diversification and maintaining market share before generic entry.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Incyte Corporation:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 75/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Incyte Corporation (INCY) at 75/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Buy. Incyte scores 91/100 on Growth Compounder metrics, driven by 18% revenue CAGR and expanding specialty pharma margins, while a 77/100 Value Compounder score at 18.1× forward P/E reflects reasonable valuation for the biotech cohort. Key
INCY's current Stocky Verdict is 75/100, placing it in the "Buy" band. This composite combines a 91/100 Compounder score, 66/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Incyte Corporation yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Incyte Corporation scores 66/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Incyte Corporation's Vulnerability Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Incyte Corporation.
Sign up free and unlock the full analysis on INCY — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for INCY in the app.
